A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymSHR-A1811-1-101
StatusFinished
Effective start/end date28/09/20 → 31/12/22